

pharmaceutical composition, a recombinany polypeptide, and a diagnostic agent for tumors;

Group III, claim 21, drawn to an antibody;

Group IV, claims 22-24, drawn to an antigen presenting cell; and

Group V, claims 25-27, drawn to a cytotoxic T lymphocyte.

For the purpose of examination of the present application, Applicants elect, with traverse, Group II, claims 5-19 and 28.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact John W. Bailey (Reg. No. 32,881) at the telephone number below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

John W. Bailey, #32,881

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

JWB/end  
0020-4872P